Immuneering (IMRX) Piper Sandler 36th Annual Healthcare Conference summary

Company overview and approach to cancer therapies

• Focuses on overcoming cancer's adaptability and similarity to healthy cells by targeting the MAP kinase pathway, particularly MEK, to improve both tolerability and durability of treatments.

• Developed a proprietary informatics platform to identify optimal inhibition timing, leading to the deep cyclic inhibition mechanism.

Deep cyclic inhibition and lead asset 104

• Deep cyclic inhibition delivers intense, short pulses of pathway inhibition, achieving above IC90 for several hours daily, then allowing rapid drug clearance to restore normal signaling.

• This approach aims to exploit differences in signaling needs between tumor and healthy cells, improving tolerability and efficacy.

Clinical data and early results

• Phase IIA expansion in pancreatic cancer showed a complete response in the first patient and a partial response in the second, both rare outcomes for this indication.

• Initial overall response rate was 40% and disease control rate 80%, both exceeding historical chemotherapy benchmarks.

• Safety profile is highly favorable, with only one grade 3 adverse event (rash) among 54 patients, supporting combinability.